Fluorometholone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fluorometholone: From Ocular Inflammation to Postinfectious Vasculitis
One-Sentence Summary
Fluorometholone is a topical, low-penetration ophthalmic corticosteroid; formal original-indication and mechanism-of-action data are currently missing from this evidence pack (flagged as data gaps). The TxGNN model’s top-ranked prediction is Postinfectious Vasculitis, but this candidate has 0 clinical trials and 0 publications — the score is model-only with no mechanistic or clinical support. Two other candidates in this same evaluation batch (post-bacterial disorder, punctate epithelial keratoconjunctivitis) carry real clinical-trial and literature evidence and are far stronger candidates than the top-ranked one; see the note below.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file — no approved license/indication text available (see Data Gaps) |
| Predicted New Indication | Postinfectious Vasculitis |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 (model prediction only) |
| US/Local Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged DG002, High severity in this evidence pack). Based on the repurposing-rationale text accompanying these predictions, fluorometholone is consistently characterized as a topical, low-penetration ophthalmic corticosteroid — a class used for steroid-responsive ocular surface and anterior-segment inflammation, not for systemic anti-inflammatory or vasculitis treatment.
For the top-ranked prediction, postinfectious vasculitis, the evidence pack’s own analysis states there is no pharmacological basis or route-of-administration support for this indication: vasculitis is a systemic disease, while fluorometholone is a topical ocular agent with negligible systemic exposure. The 99.91% TxGNN score reflects the model’s internal ranking only, with zero clinical trials and zero literature backing it (clinicaltrials.gov, ICTRP, and PubMed searches on 2026-04-21 all returned 0 results). This should be treated as a hypothesis-generating signal only, not an evidence-supported repurposing lead.
Note on stronger candidates in this batch: This evidence pack evaluated 10 candidate indications for fluorometholone. Two ranked lower by TxGNN score but carry materially better evidence and are worth separate follow-up: post-bacterial disorder (rank 2, L3, “Research Question” — includes a completed trachomatous entropion perioperative trial and an upcoming Phase 2 bacterial corneal ulcer trial, both ophthalmic and mechanistically coherent) and punctate epithelial keratoconjunctivitis (rank 6, L3, “Proceed with Guardrails” — supported by 2 relevant reviews, consistent with fluorometholone’s established anti-inflammatory use in post-keratoconjunctivitis sequelae, with a flagged risk of steroid use masking active infection).
Clinical Trial Evidence
Currently no related clinical trials registered for Postinfectious Vasculitis.
Literature Evidence
Currently no related literature available for Postinfectious Vasculitis.
US Market Information
No marketing authorizations on file. Fluorometholone’s local regulatory status is recorded as 未上市 (Not Marketed) with 0 licenses in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all currently unavailable — DDI query returned “not_found,” and TFDA label warnings/contraindications are flagged DG001, Blocking severity, meaning this candidate cannot yet pass initial safety screening.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (postinfectious vasculitis) has no clinical trials, no literature, and no mechanistic plausibility per the evidence pack’s own analysis — it is a pure model-score artifact. Separately, a Blocking-severity data gap (missing TFDA label warnings/contraindications) prevents this drug from clearing initial safety screening (S1) for any indication.
To proceed, the following is needed:
- TFDA package-insert warnings/contraindications (source: TFDA official site, PDF parsing) — required to clear S1 safety screening
- Mechanism-of-action data from DrugBank API — required for mechanistic-relevance analysis
- If pursuing a repurposing candidate for this drug, consider redirecting evaluation toward post-bacterial disorder or punctate epithelial keratoconjunctivitis, which already have trial/literature support within this same batch, rather than the top-ranked but evidence-free postinfectious vasculitis candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.